Microsatellite instability in hematological malignancies hypermutation vs. immune control- who is challenging who?

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Maletzki, Claudia ^a   Stier, Saskia ^a   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Immunosurveillance; Leukemogenesis; Microsatellite instability; Secondary leukemia; Therapy related AML MDS; Tumor specific antigen

Indexed keywords

TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CONTROL; CELLULAR IMMUNITY; FRAMESHIFT MUTATION; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LEUKEMOGENESIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATION RATE; MYELODYSPLASTIC SYNDROME; SOMATIC HYPERMUTATION; TUMOR ESCAPE;

EID: 84885819105     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25419     Document Type: Article

References (9)

1. Sellick GS, Lubbe SJ, Matutes E, Catovsky D, Houlston RS. Microsatellite instability indicative of defects in the major mismatch repair genes is rare in patients with B-cell chronic lymphocytic leukemia: Evaluation with disease stage and family history. Leuk Lymphoma 2007; 48:1320-2; PMID:17613760; http://dx.doi.org/10.1080/10428190701361844
2. Casorelli I, Bossa C, Bignami M. DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias. Int J Environ Res Public Health 2012; 9:2636-57; PMID:23066388; http://dx.doi.org/10.3390/ijerph9082636
3. Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004; 104:822-8; PMID:15090454; http://dx.doi.org/10.1182/blood- 2003-11-3938
4. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006; 79-80:153- 70; PMID:17277075; http://dx.doi.org/10.1093/bmb/ ldl020
5. Garbe Y, Maletzki C, Linnebacher M. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes. PLoS One 2011; 6:e26517; PMID:22110587; http://dx.doi.org/10.1371/journal. pone.0026517
6. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 134:988-97; PMID:18395080; http://dx.doi.org/10.1053/j.gastro.2008.01.015
7. Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 2004; 4:14; PMID:15563124
8. Maletzki C, Schmidt F, Dirks WG, Schmitt M, Linnebacher M. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: Frameshift peptides for treating MSI(+) blood cancers. Eur J Cancer 2013; In press; PMID:23561850; http:// dx.doi.org/10.1016/j.ejca.2013.02.035
9. Buckowitz A, Knaebel HP, Benner A, Bläker H, Gebert J, Kienle P, et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 2005; 92:1746-53; PMID:15856045; http://dx.doi. org/10.1038/sj.bjc.6602534